SCHEMBL313808

SCHEMBL313808

Nc1ncc2ccnc-2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MASP2 O00187 1/20 0.44
AOC3 Q16853 1/20 0.40
NPY5R Q15761 2/20 0.35
HPGDS O60760 3/20 0.35
LTA4H P09960 1/20 0.35
IKBKE Q14164 1/20 0.33
TBK1 Q9UHD2 1/20 0.33
CDK5 Q00535 2/20 0.33
CDK5R1 Q15078 2/20 0.33
BMPR1B O00238 1/20 0.33
PIK3C2G O75747 1/20 0.33
CDKL5 O76039 1/20 0.33
PIM1 P11309 1/20 0.33
TYK2 P29597 1/20 0.33
CLK2 P49760 1/20 0.33
DYRK1A Q13627 1/20 0.33
STK32B Q9NY57 1/20 0.33
PI4KB Q9UBF8 1/20 0.33
IRAK3 Q9Y616 1/20 0.33
NUDT1 P36639 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9026285 0.74 CYP2A6 (0.43) NPY5RHPGDS
SCHEMBL7220055 0.74 NPY5R (0.38) NPY5RHPGDS
SCHEMBL1983843 0.72 MASP2 (0.39) MASP2LTA4HIKBKETBK1
SCHEMBL4585526 0.71 NISCH (0.36) NPY5RHPGDSDYRK1A
SCHEMBL28175769 0.69 GSK3B (0.36) NPY5RHPGDS
SCHEMBL15880173 0.69 HPGDS (0.33) NPY5RHPGDS
SCHEMBL27647142 0.69 HPGDS (0.33) NPY5RHPGDS
SCHEMBL1441687 0.68 ALDH1A1 (0.37) NPY5RHPGDS
SCHEMBL844876 0.68 AKT1 (0.42) NPY5RHPGDS
SCHEMBL8816338 0.68 PIN1 (0.43) NPY5RHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4341264-B1 PYRROLOPIRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LEISHMANIASIS DRUGS FOR NEGLECTED DISEASES INITIATIVE (CH) 2025-04-02 EP claimed
EP-4341264-A1 PYRROLOPIRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LEISHMANIASIS Drugs for Neglected Diseases Initiative (CH) 2024-03-27 EP claimed
WO-2022243877-A1 PYRROLOPIRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LEISHMANIASIS DRUGS FOR NEGLECTED DISEASES INITIATIVE (CH) 2022-11-24 WO claimed
EP-4092030-A1 PYRROLOPIRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LEISHMANIASIS Drugs for Neglected Diseases Initiative (CH) 2022-11-23 EP claimed
WO-2020235902-A1 HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF 주식회사 보로노이 (KR) 2020-11-26 WO claimed
US-20110218189-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. ORGANON (NL) 2011-09-08 US claimed
EP-2294071-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. Organon (NL) 2011-03-16 EP claimed
WO-2009124965-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. ORGANON (NL) 2009-10-15 WO claimed
WO-2009049028-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS TARGEGEN INC. (US) 2009-04-16 WO claimed
CN-1863538-A Nucleoside derivatives for treating hepatitis c virus infection GENELABS TECHNOLOGIES (US) 2006-11-15 CN claimed
US-20260001887-A1 CYCLIN-DEPENDENT KINASE INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2026-01-01 US disclosed
EP-4341264-B1 PYRROLOPIRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LEISHMANIASIS DRUGS FOR NEGLECTED DISEASES INITIATIVE (CH) 2025-04-02 EP disclosed
CN-115244055-B Pyrimidine five-membered ring derivative and application thereof 江苏先声药业有限公司 2024-09-03 CN disclosed
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed
EP-4341264-A1 PYRROLOPIRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LEISHMANIASIS Drugs for Neglected Diseases Initiative (CH) 2024-03-27 EP disclosed
CN-1863538-A Nucleoside derivatives for treating hepatitis c virus infection GENELABS TECHNOLOGIES (US) 2006-11-15 CN disclosed
US-20060223797-A1 ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION 2006-10-05 US disclosed
WO-2006105372-A2 ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2006-10-05 WO disclosed
EP-1023889-B1 A hair lotion for preventing hair loss comprising extracts of hop, rosemary and Swertia, further containing silanodiol salicylate COLOMER GROUP SPAIN S L (ES) 2003-04-09 EP disclosed
EP-1023889-A1 A hair lotion for preventing hair loss comprising extracts of hop, rosemary and Swertia, further containing silanodiol salicylate Revlon Consumer Products Corporation (US) 2000-08-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223797-A1 ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS HSP90AB2P, HSP90AB1, HSP90AA1 MASP2 2384/4885AOC3 3764/4885NPY5R 4046/4885
US-20110218189-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS PRKCZ, PRKCQ, PRKCD MASP2 4501/4885AOC3 4076/4885NPY5R 517/4885
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP MASP2 1701/4885AOC3 3458/4885NPY5R 4509/4885
US-20260001887-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK4, CCNC, CDK2 MASP2 4849/4885AOC3 3360/4885NPY5R 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.